Obesity News

Shortages of tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, have been resolved, the FDA announced.

Tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications with no significantly higher risk for adverse events, according to findings from a network meta-analysis published in Obesity.

SAN DIEGO — Obesity represents a significant barrier to treatment effectiveness, and by extension treatment satisfaction, in rheumatoid arthritis, according to data presented at the 2024 Congress of Clinical Rheumatology West.

SAN DIEGO — Although most osteoarthritis experts agree that diet and exercise are critical to disease management, detailed guidance on either remain lacking, according to a presenter at the 2024 Congress of Clinical Rheumatology West.

In a phase 2a trial of patients with obesity-related HF with preserved ejection fraction, a novel controlled metabolic accelerator was associated with weight loss at 3 months compared with placebo.

SAN DIEGO — GLP-1 agonists and other drugs that have recently made headlines for their weight loss applications will be useful in helping patients meet goals in psoriatic arthritis and other rheumatic diseases, according to a speaker here.

Decreases in body weight and HbA1c induced by GLP-1 receptor agonists and other diabetes drugs can reduce the risk for cardiometabolic complications for adults newly diagnosed with type 2 diabetes, researchers reported.

A quarter of adults would consider using an injectable weight loss drug without consulting a health care provider, according to the results of a survey from The Ohio State University Wexner Medical Center.

A recently proposed U.S. Senate bill aims to crack down on social media influencers and others online who make misleading comments about pharmaceutical drugs.